Exforge HCT

August 2009
Pharmaceutical Representative;Aug2009, Vol. 39 Issue 8, p11
The article reports the approval given to Novartis AG' Exforge HCT (amlodipine/valsartan/hydrochlorothiazide), a drug that treats blood pressure. It notes the effectivity of the drug, along with the combination of three medications such as calcium channel blocker, angiotensin receptor blocker, and diuretic. The company claims that the drug is a new option for patients who have tried other medications, but failed.


Related Articles

  • Valturna for hypertension.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA8 

    The article reports on the approval of Valturna, a combination of direct renin inhibitor and angiotension receptor blocker from Novartis AG, in the treatment of hypertension. It states that the drug can also be used as initial therapy to patients who take in multiple drugs to achieve their blood...

  • Increased Diuretic Use Warranted.  // Kidney;Jan/Feb99, Vol. 8 Issue 1, p21 

    Discusses the findings of a study which analyzed the reasons behind the decrease in the use of diuretics in the treatment of hypertension. Perception that diuretics produced adverse metabolic effects and did not reduce coronary heart disease events; Recommendation for increased use of diuretics...

  • Pharmacological Properties of Indapamide. Bataillard, Alain; Schiavi, Pierre; Sassard, Jean // Clinical Pharmacokinetics;1999 Supplement, Vol. 37 Issue 1, p7 

    Indapamide is a thiazide-related diuretic drug with antihypertensive properties. Its blood pressure-lowering action has been repeatedly demonstrated in acute as well as chronic conditions in various genetically and nongenetically determined forms of hypertension. In rats, the maximally effective...

  • Novartis Gets Approval for Combination Medication.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p38 

    The article reports on the approval of Novartis Pharmaceuticals Corp.'s Tekturna HCT blood pressure combination drug by the U.S. Food and Drug Administration (FDA). It states that the drug is a combination of Tekturna and diuretic hydrochlorothiazide (HCTZ), one of the most commonly used high...

  • WHAT TO WATCH OUT FOR WITH thiazides. Kirschenbaum, Harold L.; Rosenberg, Jack M. // RN;Jul83, Vol. 46 Issue 7, p28 

    Provides guidelines on administering thiazide diuretics for high blood pressure in patients with normal renal function. Mechanism of action of thiazide diuretics; Side effects of thiazide diuretics; Overview of interactions of thiazide with other drugs.

  • Low-dose hydrochlorothiazide in the therapeutic strategy of hypertension: focus on the preserved metabolic profile. Asmar, Roland G.; Asmar, Jennifer T. // Hot Topics in Hypertension;2011, Vol. 4 Issue 13, p19 

    For more than 50 years following the discovery of thiazide and thiazide-like diuretics, these medications are still at the center stage of antihypertensive therapy. Thiazides are often crucial for aggressive management of hypertension in combination with other medications such as...

  • Use of calcium channel blockers after stroke is not associated with poor outcome. Dowlatshahi, Dar; Fang, Jiming; Kawaja, Marc; Hakim, Antoine // Journal of Neurology;Nov2006, Vol. 253 Issue 11, p1478 

    Control of hypertension is essential for the secondary prevention of stroke. Although several trials have assessed the role of calcium channel blockers (CCBs) in the acute stroke, few address their safety and efficacy in secondary prevention. The recovery process after stroke requires neurite...

  • VALTURNA 150mg/160mg.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, pA21 

    The article offers information on Valturna 150milligrams (mg)/160mg antihypertensive agent from Novartis AG. The drug acts as monotherapy for hypertension or with other antihypertensives. As initial therapy in patients probably require multiple drugs to attain blood pressure goals. Valturna...

  • 2 Companies Stumble Over PAH; Therapies Prove Difficult. Winter, Peter // BioWorld Insight;8/27/2012, Vol. 20 Issue 35, p3 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics